Please select the option that best describes you:
Topics:
Gynecologic Cancers • Endometrial Cancer • Medical Oncology • ASCO Journal Club • Journal Club ft. NEJM publications • Gynecologic Oncology
For patients with advanced endometrial cancer, are the improved outcomes in PFS from DUO-E/RUBY/NRG-GY018 sufficient to move immunotherapy to the frontline for all presuming FDA approval?
Are there patients for whom you would still reserve IO for salvage/recurrent setting (eg IO + lenvatinib)? Would you base this on MMR status or other clinical factors?
Answer from: at Community Practice
The standard of care for metastatic endometrial cancer is systemic therapy with chemotherapy and now with or without immunotherapy. With this approach to therapy, there is a roughly 70% reduction in the risk of progression or death across three separate trials for the dMMR population (RUBY, GY018, A...
Sign in or Register to read more
Answer from: at Academic Institution
The addition of immunotherapy to chemotherapy should certainly be considered the standard of care for patients with dMMR tumors. At the 2023 ESMO meeting, Dr. @Slomovitz and team made a compelling argument to further strengthen the use of immunotherapy in the front line. Using the RUBY patient ...